GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G.Barekat Pharm (XTEH:BRKT1) » Definitions » Institutional Ownership

G.Barekat Pharm (XTEH:BRKT1) Institutional Ownership : 0.00% (As of May. 16, 2024)


View and export this data going back to 2017. Start your Free Trial

What is G.Barekat Pharm Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, G.Barekat Pharm's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, G.Barekat Pharm's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, G.Barekat Pharm's Float Percentage Of Total Shares Outstanding is 0.00%.


G.Barekat Pharm Institutional Ownership Historical Data

The historical data trend for G.Barekat Pharm's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G.Barekat Pharm Institutional Ownership Chart

G.Barekat Pharm Annual Data
Trend Mar16 Mar17
Institutional Ownership
- -

G.Barekat Pharm Semi-Annual Data
Mar16 Mar17
Institutional Ownership - -

G.Barekat Pharm Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


G.Barekat Pharm (XTEH:BRKT1) Business Description

Traded in Other Exchanges
N/A
Address
No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN
G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.

G.Barekat Pharm (XTEH:BRKT1) Headlines

No Headlines